• Asian Journal of Business Environment
• /
• v.11 no.4
• /
• pp.39-45
• /
• 2021

Purpose: This study is designed to investigate the extent and nature of climate change disclosure of listed pharmaceutical companies of Bangladesh. Research design, data and methodology: In order to perform this research, a content analysis methodology is used. A climate change disclosure index is constructed to examine 12 different climate change disclosure issues. Information is collected from the annual reports of 29 pharmaceutical companies listed on the Dhaka Stock Exchange for the year 2019. Results: This study finds that only 48.28% of the sample companies provided disclosure on at least one issue regarding climate change. 'Energy savings' is the mostly disclosed issue whereas 'Pollution control expenditure', 'Biodiversity conservation initiatives' are the least disclosed issues. Research implication: This study concludes 64.29% of the companies examined, use less than five sentences for climate change disclosure, which depicts unsatisfactory disclosure practices regarding climate change issues. Study findings would be helpful for different industries of Bangladesh to implement efficient climate change reporting Practice. Future studies can be conducted on other industries to obtain more comprehensive result.

• Journal of the Korean Operations Research and Management Science Society
• /
• v.42 no.3
• /
• pp.35-49
• /
• 2017

The main objective of this paper is to empirically analyze the efficiency effects of mergers on Korean pharmaceutical firms and suggests managerial or policy implications for managers or policy makers. This study selects non-merging control firms close to the size of merging firms, as well as a set of merging firms, and measures the effects of mergers on efficiency three years before and after the merger using the non-parametric data envelopment analysis (DEA) method. To compare the differences of efficiency means among several groups, Wilcoxon rank sum test or Wilcoxon signed rank test is used. It showed that the long-term effects after the merger appeared partially. Furthermore, it was observed that there was no difference statistically in the efficiency between merging and non-merging firms. Also, there was no difference statistically in the efficiency between the pre- and post-merger periods. In conclusion, there was not any observed synergy effect through group (or affiliated) mergers between affiliates or related mergers for Korean pharmaceutical firms.

• Bulletin of the Korean Chemical Society
• /
• v.35 no.7
• /
• pp.2210-2212
• /
• 2014

• Journal of the Korea Academia-Industrial cooperation Society
• /
• v.19 no.5
• /
• pp.389-398
• /
• 2018

An MRA is considered to be an important policy tool within the WTO for overcoming technical barriers to trade. A number of studies on the economic impact of MRAs have demonstrated their positive economic effects. However, no studies have been conducted on MRAs in the pharmaceutical industry since analysis has been limited to industries as a whole or certain industries where some data were accumulated. Therefore, this paper analyzed the economic impact of MRAs for GMP inspection exemption in the pharmaceutical industry through the Conditional Valuation Method (CVM), a valuation technique for non-market goods. Pharmaceutical companies were asked whether or not they were willing to pay for the Korea-EFTA MRA through double-bounded dichotomous choice (DBDC) questions. The final WTP was estimated using the utility difference model developed by Hanemann (1984). As a result, annual economic effects on the pharmaceutical industry were estimated to be between KRW7.03 billion to KRW15.8 billion.

• Journal of the Korea Academia-Industrial cooperation Society
• /
• v.12 no.3
• /
• pp.1270-1277
• /
• 2011

Since the pharmaceutical industry is a research oriented sector, the research and development capability based on the qualified R&D manpower is one of the key success factors to strengthen the national competitiveness. Securing the appropriate number of researcher needed for the research activities in these fields is an important precondition for a government policy that aims for a strongly knowledge-intensive the pharmaceutical industry growth. In this study, we conducted and analyzed a delphi survey of the experts(the principal investigators) with expertise in these pharmaceutical research areas. The current and future requirements for the pharmaceutical science research personnel including medical doctors have been evaluated, extending the year 2017. The results of this study can be summarized as follows; First, in 2007 the field of pharmaceutical R&D personnel is currently under-supplied as many as about 5,600 people. The rate of under-supplied is about 18.1%. Second, in 2017 the evaluation shows that the R&D personnel in this field will be more severely under-supplied as many as 13,500 people. The rate of under-supplied will be about 28.6%. As a result, the confrontation of demand and supply evaluation shows that, in general, severe shortages of R&D manpower in the field of pharmaceutical will result if there are not adequate manpower policy adjustment.

• The Korean Journal of Health Service Management
• /
• v.9 no.4
• /
• pp.157-169
• /
• 2015

Objectives : The aim of this study was to investigate the effect of various Republic of Korea policies, including the medicine cost rationalization policy implemented By investigating the management strategy/performance changes of the industry caused by such policies. Methods : Pharmaceutical companies listed on the national stock exchange and the KOSDAQ were examined for 10 years from 2004 to 2013. Their financial statements were collected and market changes before and after drug price policy implementations were compared. Results : From the result of this research, among the medicine related policies, the drug price rationalization policy was found to have a significant effect on business management strategies in terms of safety, profitability and growth potential after its implementation. After the drug pricing transparency policy was implemented, management strategies were affected significantly in terms of safety and profitability. Conclusions : As a result, all of the medicine related policies were found to have regulatory effects. Based on these findings, implications, research limitations and future study plans are presented.

• The Korean Journal of Health Service Management
• /
• v.13 no.3
• /
• pp.105-114
• /
• 2019

Objectives: This study aimed to provide a comprehensive analysis of the relationship between the service quality of the Korea Health Industry Development Institute (KHIDI), along with the utilization of and customer satisfaction with its export supporting program, and the export performance of Korean pharmaceutical companies. Methods: An online and offline survey was conducted on Korean pharmaceutical companies that have used the export supporting program provided by KHIDI. Data on the service quality of KHIDI, utilization of and customer satisfaction with the export supporting program, and company export performance were collected via survey. Results: Results indicated that systemizing and reliability service factors of the export supporting program have a significant impact on customer satisfaction, and customer satisfaction has a significant impact on utilization of the export supporting program. Furthermore, customer satisfaction and utilization of the program have a significant impact on company expectations regarding future export performance. Conclusions: As a result, service quality, utilization, and customer satisfaction were found to affect Korean pharmaceutical company's expectations regarding their future export performance. The results of this study can significantly impact the development of export supporting programs.

• Journal of Digital Convergence
• /
• v.20 no.5
• /
• pp.423-432
• /
• 2022

Due to the development of treatments due to COVID-19, the Firm-value of the pharmaceutical industry has increased. However, the development of treatments has been delayed, and the development of overseas markets has become difficult due to COVID-19. Therefore, this study aims to present an efficient management plan for each firm by analyzing the management efficiency of these firms. As for the research method, DEA analysis was conducted for the pharmaceutical industry. Through this method, we propose values of input variables that inefficient companies can benchmark. As a result of the analysis, there was no significant difference in management efficiency before and after COVID-19, but it was confirmed that the management efficiency of certain Firm decreased. Through this study, it is possible to judge a Firm's survival competitiveness and management strategy, and furthermore, a plan to continuously grow and enhance competitiveness was suggested.

• Journal of Pharmaceutical Investigation
• /
• v.23 no.4
• /
• pp.231-254
• /
• 1993

These days, it is not uncommon that a same kind of drug is circulated globally. However, the qualities of excipients used in the same drug have to be sometimes different depending on the different requirements in the qualities stipulated by each country. For a supplier of pharmaceutical excipients, it is generally necessary to carry out different tests on the same kind of testing criteria depending on the country of destination. Thus, the discrepancies between compendium requirements of pharmaceutical excipients create severe problems in various area of industrial activities. The decision of the United States Pharmacopoeia, European Pharmacopoeia and Japanese Pharmacopoeia Commissions to harmonize the requirements is a unique chance for the industries to overcome these problems. On the other hand, discrepancies of general test methods and requirements in each monograph of pharmaceutical excipient between the compendia valid at present are in most cases extensive. Consequently their harmonization needs a lot of detailed work requiring strong support from the industry. Based on these circumstances, pharmaceutical excipients councils have been established first in U.S.A. and successively in Europe and in Japan to contribute to the harmorization process. We should like to review here the progress since the Orlando Conference in 1991 and comment about the matters at issue with regard to the international harmonization of pharmaceutical excipients.

• Korea Journal of Hospital Management
• /
• v.5 no.1
• /
• pp.24-39
• /
• 2000

This paper aims to analyze the effects that marketing mix variables have on the marketing performance of pharmaceutical manufacturers. It examines how product characteristics, price, marketing channel and promotion effort influence the sales and market share of anti-ulcer drugs in the markets for clinics and hospitals separately. Empirical results from 29 products of anti-ulcer drugs show that sales in hospitals are affected by the profit per prescription to the physician, brand name drugs relative to generics, and the age of ingredients since its introduction to the markets. Profit per prescription to the hospital, relative price, age of ingredients and promotion effort have positive effects on the market share.